To identify genes that may be relevant to the molecular action of antidepressants, we investigated transcriptional changes induced by the selective serotonin reuptake inhibitor paroxetine in a serotonergic cell line. We examined gene expression changes after acute treatment with paroxetine and sought to validate microarray results by quantitative PCR (qPCR). Concordant transcriptional changes were confirmed for 14 genes by qPCR and five of these, including the adrenomedullin gene (Adm), either approached or reached statistical significance. Reporter gene assays showed that a SNP (rs11042725) in the upstream flanking region of ADM significantly altered expression. Association analysis demonstrated rs11042725 to be significantly associated with response to paroxetine (odds ratio ¼ 0.075, Po0.001) but not with response to either fluoxetine or citalopram. Our results suggest that ADM is involved with the therapeutic efficacy of paroxetine, which may have pharmacogenetic utility.
Introduction
It is generally thought that 2 weeks of antidepressant treatment is required before significant clinical therapeutic benefit becomes apparent, but there is some evidence that effects can be seen earlier. [1] [2] [3] [4] Therefore, it is possible that the therapeutic action of antidepressants is initiated by gene expression changes in the early stages of treatment and antidepressant pharmacogenomic studies may provide a means to uncover candidate genes relevant to antidepressant response. Indeed, genes such as ABCB1, BDNF, SLC6A4 and TPH1, which have been associated with antidepressant response, [5] [6] [7] [8] show acute antidepressant-induced expression changes. [9] [10] [11] [12] RN46A cells are committed to a neuronal lineage and express the serotonin transporter (Slc6a4), 13 the pharmacological target of selective serotonin reuptake inhibitors (SSRIs). Differentiated RN46A cells are a powerful model system for investigating SSRI pharmacogenomics as they emulate serotonergic neurons of the raphe nuclei, regions of the central nervous system, which have the highest density of Slc6a4 14 and the greatest accumulation of extracellular serotonin after SSRI exposure. [15] [16] [17] However, only one previous study has exposed serotonergic neurons to antidepressants for microarray studies. 18 In this study, we employed the RN46A cell line as a model system to uncover early transcriptional changes in response to the SSRI paroxetine and to identify genes, which may be associated with the clinical response to this antidepressant or other selective serotonin reuptake inhibitors.
Results

DNA microarray analysis of paroxetine-treated differentiated RN46A cells and validation of changes in transcript abundance
Microarray analysis, comparing differentiated RN46A cells cultured in the presence or absence of paroxetine for a 36 h period, revealed significant differences in the abundance of 253 transcripts (Supplementary Table S1 ). Quantitative PCR (qPCR) assays were developed and applied to 15 of the genes that had significant expression changes, and 14 genes showed concordant expression differences by both qPCR and microarray analyses (Table 1 ). Id2 and Ucn2 had statistically significant (Po0.05) increases in transcriptional expression, whereas the expression changes of Ankrd37, Adm and Bnip3 approached conventional statistical significance (Po0.1). After consideration of the five genes, the human homologue of Adm was chosen for further examination as this gene had the greatest paroxetine-induced expression change, as determined by expression analyses, and ADM is the only homologue of these genes which has been previously identified in connection to a mood disorder 19 or other psychiatric conditions. 20, 21 Reporter gene analysis of ADM upstream regulatory region variant A 2.2 kb region upstream of the coding exons of ADM was sequenced in 12 unrelated individuals. A C4A polymorphism (rs11042725) was detected 1923 bp upstream of the translational start site. The two allelic variants of this fragment were cloned into the pGL3-Basic vector to observe their effects on basal transcription rates. pGL3-Basic constructs containing the ADM variants were transiently transfected into COS-7 and RN46A cells. The expression of the luciferase gene under the control of either of the ADM variants was significantly higher than the background activity of the empty pGL3-Basic vector in both cell lines (Figure 1 ). In the COS-7 cell line there was no significant difference in expression among the constructs. However, in undifferentiated RN46A cells, the A allele had 55% greater expression (Po0.05) of luciferase than the C allele. This result encouraged us to explore whether this SNP is associated with antidepressant response phenotypes in a clinical setting.
Genotyping of rs11042725
A one-tube, allele-specific PCR was devised to interrogate rs11042725 ( Figure 2 ). The accuracy of the assay was confirmed by comparing the genotyping data with the DNA sequencing of the 12 individuals originally used for the detection of polymorphisms in ADM. A total of 565 individuals in a family study of depression and its treatment were successfully genotyped for rs11042725. The frequencies of allele combinations are shown in Table 2 . A w 2 -test showed that the observed genotype frequencies were consistent with Hardy-Weinberg equilibrium (w 2 ¼ 0.48, P ¼ 0.49).
Association studies
Of the 565 individuals successfully genotyped (from 191 families), 181 individuals had no lifetime mood disorder diagnosis. Of the 374 individuals with a lifetime mood disorder diagnosis, 285 had major depression and 99 had a 
Discussion
Differentiated RN46A cells were treated for 36 h with paroxetine and 253 genes were found to have changes in transcript abundance by microarray analysis. Out of 15 genes examined by qPCR methods, Id2 and Ucn2 were found to have significant paroxetine-induced increases in expression. A further three genes, Ankrd37, Adm and Bnip3 had increases in expression, which were close to statistical significance and were considered to be putative paroxetineregulated genes. This may appear to be a low validation rate of gene expression changes but the observed transcriptional changes were relatively small and it is acknowledged that low fold changes in gene expression are more difficult to validate. 22, 23 However, 14 of the 15 genes examined showed concordant transcriptional changes between the two analyses of gene expression which compares favourably with typically reported rates of concordance between microarray and qPCR analysis. 22, [24] [25] [26] Some of our candidate paroxetine-regulated genes have been previously shown to be induced by antidepressant treatment or to have biological functions relevant to antidepressant action. Id2, a helix-loop-helix gene which is involved in cell cycle regulation 27 and is upregulated in proliferating cells, 28 shows increased levels of transcript in the rat hippocampus after moclobemide or amitriptyline treatment.
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Bnip3 transcript is upregulated in a This assay generates: A a 690 bp internal control band; B a 500 bp product corresponding to the A allele; and C a 279 bp band, which represents the C allele. S1 is homozygous for the A allele, S2 is a heterozygote and S3 is homozygous for the C allele. Association of ADM with paroxetine response DM Glubb et al neuroblastomaxglioma hybrid cell line after treatment with imipramine, mianserin or milnacipran. 30 Ucn2 modulates the activity of neurons in the dorsal raphe nucleus, 31 and has effects on the serotonergic system 32 and stress-related behaviours. 33 Adm is a regulatory peptide involved in the regulation of neural differentiation and apoptosis. 34 A neuroprotective function for Adm has been suggested after Miyashita et al. 34 showed that transgenic mice, which overexpress Adm, show enhanced vascular regeneration and neurogenesis after cerebral ischaemia. Conversely, mice lacking Adm in the brain show overanxious behaviour. 35 Differential expression of ADM has been observed in schizophrenia, 36 and ADM levels have been associated with mood and other psychiatric disorders. [19] [20] [21] Thus, the biological relevance and the relatively high expression change of Adm in response to paroxetine persuaded us to choose the human homologue of Adm as a candidate gene for genetic association studies in depressed individuals.
We examined whether a SNP (rs11042725) in the promoter of ADM was associated with mood disorders or SSRI antidepressant response. The only significant result was an association of the C/C genotype with lower likelihood of response to paroxetine. Reporter gene analysis showed that there was significantly less expression of the C allele than the A allele in undifferentiated RN46A cells. Therefore, the association of rs11042725 with response to paroxetine may be due to reduced expression of the C variant in cells of neuronal/serotonergic origin. The C/C genotype was not found to be associated with a lesser chance of response to fluoxetine or citalopram, so these observations suggest that upregulation of ADM by paroxetine may have a role specifically in response to this antidepressant.
There are several limitations to this study that should be acknowledged. With respect to the clinical data collection, prospectively assessed studies and surveys are generally considered to be superior to retrospectively patient-reported data due to the elimination of patient recall or cognitive bias. 37 However, patient self-report global improvement scales have been shown to confirm results from antidepressant treatment outcomes measured by trained assessors 38 or significantly correlate with clinician-rated depression scales. 39 Also, it is accepted that the number of people who were prescribed paroxetine in this study is small (n ¼ 66) and, therefore, the association of rs11042725 should be interpreted with caution. The first positive study of a genetic association typically demonstrates larger effects than subsequent studies and non-replication is common when further studies use larger sample sizes. [40] [41] [42] However, there is some evidence to suggest that a P-value of less than 0.001, such as in this study, is predictive of further replication. 40, 43 Finally, it is worth noting that the RN46A cells used for the in vitro reporter gene analysis were, of necessity, not induced to undergo full differentiation and therefore they will be of quite a different phenotype to the mature, well differentiated cells found in the mammalian central nervous system. This work has shown that antidepressant pharmacogenomics may provide candidates for antidepressant response studies. Indeed, ADM may prove to have some pharmacogenetic utility. However, replication studies using independent, well-phenotyped cohorts will be necessary to confirm the preliminary association we have observed between response to paroxetine and ADM.
Materials and methods
Differentiation of RN46A cells RN46A cells cultured at 33 1C will divide and have an undifferentiated phenotype, but after a change in medium composition and culture at 39 1C, RN46A cells differentiate and develop a more mature neuronal phenotype. 13 The differentiation of RN46A cells was carried out as previously described 13, 44 with minor modifications. RN46A cells were maintained in DMEM/F12 þ GlutaMax-I (Invitrogen, Carlsbad, CA, USA) with 5% heat-inactivated fetal bovine serum (Invitrogen) and 250 mg ml À1 geneticin (Invitrogen) at 33 1C in a humidified incubator containing 5% CO 2 . For differentiation, cells were trypsinized and resuspended in DMEM/ F12 þ GlutaMax-I with 1% heat-inactivated fetal bovine 36 .5 mg of L-glutamine (Invitrogen) and 5 ml of 100 U ml À1 penicillin/100 mg ml À1 streptomycin (Invitrogen). The cell count was adjusted to 0.6 Â 10 5 cells per ml and 1 ml of cell suspension was transferred to each well of a six-well plate (BD Biosciences, Franklin Lakes, NJ, USA) coated with collagen and fibronectin. The cells were then incubated at 39 1C in a humidified incubator containing 5% CO 2 for 8 days and the medium was replaced every second day.
Paroxetine exposure and RNA extraction After 8 days of differentiation, the cultures were incubated in medium with and without 0.5 mM paroxetine (Sigma Aldrich) for 36 h. After paroxetine exposure, RNA was extracted using Tri Reagent (Sigma Aldrich) and RNeasy MINI columns (QIAGEN, Hilden, Germany). The quantities and qualities of RNA from each sample were assessed by gel agarose electrophoresis as well as spectrophotometry.
Microarray experiments and analysis
RNA from three independent replicates of the control and paroxetine-treated cells, was sent to the Centre for Genomics and Proteomics (Auckland UniServices, Auckland, New Zealand) for microarray experiments using Affymetrix (Santa Clara, California, USA) rat 230 2.0 GeneChips. Five micrograms of RNA from each sample was used for synthesis of double-stranded cDNA. An in vitro transcription reaction was performed on the cDNA to produce biotin-labelled cRNA, which was then fragmented before hybridization to the Rat 230 2.0 Affymetrix GeneChips. The probe intensity files were imported into BRB-ArrayTools v3.5 (http:// linus.nci.nih.gov/BRB-ArrayTools.html), which was developed by Dr Richard Simon and BRB-ArrayTools Development Team. Data were filtered and then log base 2 transformation and robust multi-array average normalization was carried out before a class comparison analysis. Logratios of the treated/untreated intensities were determined and a paired t-test (with random variance model) was used to identify statistically significant (Po0.05) gene expression changes between paroxetine-treated and untreated RN46A cells. Microarray data were submitted to the European Bioinformatics Institute (www.ebi.ac.uk) under the experiment name: GSFL-RN46A-acute paroxetine exposure (ArrayExpress accession: E-MEXP-1582).
cDNA preparation Five micrograms of RNA was used from each sample for the synthesis of cDNA in a 20 ml volume with oligo(dT) 20 (Invitrogen) and SuperScript III reverse transcriptase (Invitrogen). The reactions were incubated at 50 1C for 1 h and then inactivated by heating at 70 1C for 15 min. RNaseH (Invitrogen) was added, 1 ml to each preparation and incubated for 20 min at 37 1C.
qPCR assays Eight microlitres of diluted cDNA was used as template in qPCR reactions in a 20 ml volume with the appropriate primer set (Table 5) , 200 mM dNTPs, 0.75 U Platinum Taq DNA polymerase (Invitrogen), 2.8 mM MgCl 2 and 0.5 Â Sybr-green (Sigma Aldrich). Primers were designed, where possible, to span exons and to generate a fragment of between 100 and 150 bp. The qPCR assays were performed Association of ADM with paroxetine response DM Glubb et al on a Corbett Rotor-Gene RG-3000 (Corbett Life Science, Concorde, NSW, Australia) using the following PCR conditions: 2 min at 94 1C followed by 50 cycles of 20 s denaturing at 94 1C, 20 s annealing (temperature dependent on the primer set used), 20 s extension at 72 1C and 10 s acquiring the fluorescence data (temperature dependent on the gene being assayed). An RT-negative control was used to assess whether any residual genomic DNA remained and a notemplate control was included to examine primer-dimer formation. qPCR experiments were excluded for analysis if the reaction efficiency was outside the range of 0.9-1.1 or if the r 2 value of the linear regression was less than 0.95. For the qPCR analysis, the relative quantification method was used. Our approach incorporated a standard curve to allow determination of the relative number of cDNA molecules of a given gene by using serial dilutions of an arbitrary cDNA sample. Expression of the gene of interest was normalised by the geometric mean of expression from three reference genes: deleted in azoospermia-associated protein 1 (Dazap1), LOC499709 and RGD1305222_predicted. The geometric mean is used when changes in the data are expected to occur in a relative fashion and normalization with the geometric mean of multiple reference genes is recommended to reduce error. 45 The above genes were chosen as control genes after examination of the microarray data and analysis of qPCR data for expression stability with NormFinder, 46 because they had the most stable expression following 36 h treatment of differentiated RN46A cells with 0.5 mM paroxetine.
qPCR was performed with cDNA samples in triplicate from five independent replicates of cDNA from the 36 h paroxetine-treated and untreated differentiated RN46A cells. The normalized data from the control and paroxetine-treated groups were then analysed using a paired t-test in GraphPad Prism (GraphPad, La Jolla, CA, USA) and fold-change determined.
Polymorphism detection
Genomic DNA was prepared from peripheral blood samples using a guanidium chloride extraction method followed by isopropanol precipitation. 47 DNA was resuspended in 10 mM pH 8.0-1 mM EDTA (0.5 ml). A 2.2 kb upstream region of ADM was screened for polymorphisms by direct sequencing of PCR products using 12 unrelated parents from a familybased cohort of depressed individuals. 48 The information on primer sequences and amplification conditions is available upon request.
Luciferase reporter gene assays A fragment of the upstream region of ADM (À1333 to þ 128 bp, relative to the transcription start site) was amplified using a pair of primers with KpnI and MluI restriction sites engineered into the forward (5 0 -GGGGTAC CGCTGGGCTTCAGGACATTCGATTAG-3 0 ) and reverse (5 0 -gggacgcgtactggcaatggcaaaactccga-3 0 ) primers, respectively. The PCR fragments were cloned into the pGL3-Basic vector (Promega, Madison, Wisconsin, USA), using KpnI and MluI restriction sites in the plasmid, and constructs were checked by DNA sequencing.
COS-7 cells were grown in DMEM (Invitrogen) with 10% heat-inactivated fetal bovine serum and 100 mg ml À1 penicillin/streptomycin (Invitrogen). COS-7 cells were maintained at 37 1C, whereas RN46A cells were cultured undifferentiated at 33 1C, as differentiated RN46A cells were less amenable to reporter gene assays. Both cell lines were grown in a humidified atmosphere of 5% CO 2 in air. COS-7 or RN46A cells were plated out on 24-well tissue culture plates in 1 ml of medium at a density of 5 Â 10 4 cells per ml, the day before transfection. On the day of transfection, the medium was removed and 400 ml of fresh medium was added to each well. Transient cell transfections were carried out using the lipid transfection reagent Effectene (QIAGEN). For use in transfections, plasmid DNA was diluted to 50 ng ml À1 and 95 ml of each plasmid construct was mixed with 5 ml of 50 ng ml À1 pRL-TK Renilla luciferase plasmid (Promega). For the transfection of each well of COS-7 cells, 4 ml of plasmid mix was added to 25 ml of EC buffer (QIAGEN) with 1.6 ml of Enhancer reagent (QIAGEN). The solution was mixed and incubated at room temperature for 2 min before the addition of 1.5 ml of Effectene reagent. For the transfection of each well of RN46A cells, 2 ml of plasmid mix was added to 25 ml of EC buffer with 0.8 ml of Enhancer and 2.5 ml of Effectene reagent was used.
Luciferase assays were carried out using reagents from the Dual-Luciferase reporter assay kit (Promega). 48 h after transient transfection, the medium was aspirated from the wells and cells were washed with PBS. 100 ml of cell lysis solution was added and the cells were incubated for 15 min on a shaking platform. Firefly luciferase activity was determined by adding 10 ml of cell lysate to a 96-well plate followed by addition of 50 ml of luciferase assay buffer and subsequent measurement of luminescence using a microplate luminometer LUMIstar Galaxy (BMG Lab Technologies, Offenburg, Germany). To the same wells, 50 ml of Stop & Glo reagent (Promega) was added to measure renilla luciferase-generated luminescence.
A negative expression control, consisting of empty pGL3-Basic vector, was included in each independent experiment. All plasmids were cotransfected with the internal control vector pRL-TK and the renilla luciferase data from this plasmid was used to normalize the expression of the firefly luciferase from the individual constructs. In each independent experiment, three replicate transfections were performed for all constructs. Three independent experiments were carried out in each cell line. The geometric means of the ratios of firefly/renilla luciferase from the replicate experiments were analysed by one-way analysis of variance using Tukey's multiple comparison test in GraphPad Prism. Geometric means were used as they provide the best method of summarizing ratios.
Genotyping of rs11042725
The genotyping was performed using an amplification refractory mutation system assay. Allele-specific primers (forward A allele: 5 0 -GTTAGTAGGACCCCAGAAACCCACAA Association of ADM with paroxetine response DM Glubb et al GCTA-3 0 ; reverse C allele: 5 0 -AAAGGCTAAGCCACGGGGCT TCCTGCTTGG-3 0 ) were used in combination with forward (5 0 -CACCGGAGCTCAGAGCCATATGGCAGAGTA-3 0 ) and reverse (5 0 -CCAGGGAGCACACTAACGCTTCACGTATGC-3 0 ) common primers to amplify allele-specific products as well as a fragment encompassing the regions amplified by allelespecific PCR. The PCR product generated by the common primers served as an internal control for DNA quality. The amplification refractory mutation system PCR was performed in a total volume of 10 ml containing 1 ml of genomic DNA, 2.2 ml of primer mix (0.45 mM of all primers), 200 mM dNTPs, 1 Â GC-rich reaction buffer (Roche Diagnostics NZ, Auckland, New Zealand), 1 Â GC-rich resolution buffer (Roche) and 0.25 U of Roche Taq DNA polymerase. After an initial denaturation step of 94 1C for 2 min, 10 cycles were performed at 94 1C for 30 s, 62 1C for 30 s and 72 1C for 60 s, followed by another 20 cycles in which the elongation step was extended by 5 s per cycle.
Family study of depression and personality The Molecular Genetics of Depression and Personality is a family study based on the recruitment of trios. The proband must have had a history of treatment for a major depressive episode, regardless of a history of bipolar disorder, by age 18 years or older and have two family members, preferably parents but could be siblings who were also willing to be involved. All consenting participants (probands, parents or siblings) were seen by a trained interviewer, who was supervised by one research psychiatrist. The interview was based on the Mini-International Neuropsychiatric Interview, 49 but with additional sections for the diagnosis of alcohol and drug dependence. In addition, the Mood Disorder Questionnaire 50 was included within the interview to further assist with bipolar diagnoses. All participants completed two self-report questionnaires and provided a blood sample for DNA extraction. All diagnoses were made by the psychiatrist after review of each interview.
Subjects with a history of a depressive episode were asked whether they had ever been prescribed fluoxetine, citalopram, paroxetine or other antidepressant drugs. They were asked about the dosage received and how long they took the antidepressant. To be conservative, we required that a participant had taken an SSRI for 6 weeks to be deemed an adequate trial. Participants who had completed an adequate trial were asked to rate their response to the antidepressant; where 1 ¼ very good response, 2 ¼ good response, 3 ¼ slight response and 4 ¼ minimal or no response. For this paper, analyses are limited to those with a diagnosis of major depression (that is, excluding those with bipolar disorder) and response was dichotomized into a responder (response 1 or 2) or non-responder (response 3 or 4) category.
The study had been approved by the Canterbury (New Zealand) Ethics Committee and subjects provided written informed consent. Associations between mood disorder diagnoses and genotyping were examined with w 2 -tests. Antidepressant response in those with major depression was examined by logistic regression. Further details on this cohort are available in other papers. 48, 51 
